2月11日，瑞士制药巨头诺华制药周二表示，已同意以高达31亿美元的价格收购生物制药公司Anthos Therapeutics，以加强其后期心血管药物研发管线。
据了解，Anthos由黑石(BX.US)旗下Blackstone Life Sciences和诺华制药于2019年共同创立，致力于开发、生产和商业化一种用于预防中风和防止血栓复发的治疗药物——abelacimab。
诺华制药表示，该交易预计将于今年上半年完成，公司将预先支付9.25亿美元，并可能根据后续情况支付高达21.5亿美元的额外款项。
Anthos首席执行官Bill Meury表示：“诺华制药在心血管领域拥有深厚的根基，特别适合推进abelacimab的临床开发，并将这一创新产品带给医疗保健提供者和患者。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.